Source: DGNews  |  Posted 9 years ago

By Bruce Sylvester
Special to DG News

BARCELONA, SPAIN -- October 9, 2002 -- The use of olanzapine/fluoxetine combination therapy with treatment-resistant and psychotic depression patients entails no new safety issues other than those commonly associated with olanzapine and fluoxetine monotherapy.

The finding was reported here October 7 at the 15th Congress of the European College of Neuropsychopharmachology (ECNP).

"We saw no significant differences in categorical changes in laboratory analytes, vital signs, electrocardiograms or extrapyramidal symptoms. There don